SCID

$32.9 Billion Worldwide Synthetic Biology Industry to 2027 - Featuring Amyris, Codexis and Danaher Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 13, 2022
Biotechnology, Health, Genetics, Science, Research, Technology, Disease, Synthetic biology, Engineering, Environment, Genomics, Patient, Immunodeficiency, SCID, Internet, COVID-19, Enzyme, Diagnosis, Cell, Investment, Virus, Fertilizer, Lists of diseases, Research, Epidermolysis bullosa, Growth, Industry, DNA, Pharmaceutical industry, Fine chemical, Potash

This, in confluence with increasing investments in synthetic biology, represents one of the key factors impelling the growth of the market.

Key Points: 
  • This, in confluence with increasing investments in synthetic biology, represents one of the key factors impelling the growth of the market.
  • Furthermore, significant growth in the healthcare sector and the rising number of synthetic biology research entities worldwide are positively influencing the market.
  • Key Questions Answered in This Report:
    How has the global synthetic biology market performed so far and how will it perform in the coming years?
  • What is the structure of the global synthetic biology market and who are the key players?

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Retrieved on: 
Tuesday, May 24, 2022
Epithelium, CEO, Inflammation, Degenerative disease, UC, Edu, Hyperplasia, Toxicology, Retina, Soft tissue injury, Disease, DDW, Ulcerative colitis, U.S. Securities and Exchange Commission, Homeostasis, Infection, Immunoglobulin G, Kinetics, Hearing loss, Coronavirus, GLP, Liver, FZD5, Cochlea, COVID-19, Trial of the century, SCID, Kidney, Research, IBD, Mouse, Inflammatory bowel disease, SAN, RATS, Alcoholic hepatitis, DSS, Probability, Fibrosis, Lists of disasters, Forward-looking statement, Tissue, Central nervous system, Major, Liver injury, Regeneration, Hepatocyte, Lists of diseases, Lung, Therapy, Security (finance), Eye, Annual report, Hepatitis, Institute of Liver and Biliary Sciences, GLOBE, Pharmaceutical industry, Medical imaging, Dietary supplement, WNT

These data represent the important progress and significant advances made in the scientific understanding of our lead therapeutic candidates, SZN-1326 and SZN-043, said Craig Parker, CEO of Surrozen.

Key Points: 
  • These data represent the important progress and significant advances made in the scientific understanding of our lead therapeutic candidates, SZN-1326 and SZN-043, said Craig Parker, CEO of Surrozen.
  • The data further show that SZN-1326 also reduced stromal and immune cytokine signaling and immune cell infiltration.
  • Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway.
  • However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law.

Smart Immune Announces Oral Presentation of Cell-Fate Plasticity Data of its T-cell Progenitor-Based Therapy Platform (ProTcell™) at ASGCT 2022

Retrieved on: 
Friday, May 20, 2022
Cancer, Mythic Imagination Institute, Investigational New Drug, NSG, Company, Doctor of Pharmacy, Acute leukemia, Disease, Infection, CCR7, American, HSCT, Doctor of Philosophy, AML, Patient, ILC, CXCR4, Lymphatic system, Graft-versus-host disease, Adult, Mortality, SCID, Cell, Research, Gene, FDA, Mouse, Imagine, Allotransplantation, IND, Trial, NK, Virus, Program, Leukemia, CCR9, CD161, Prognosis, Immunodeficiency, ALL, Immune system, GLOBE, Vaccine, Dietary supplement, MD

This research provides further evidence that our lymphoid progenitors have a plasticity that allows them to differentiate into both T cells and NK cells.

Key Points: 
  • This research provides further evidence that our lymphoid progenitors have a plasticity that allows them to differentiate into both T cells and NK cells.
  • Innate lymphoid cells (ILCs) are innate counterparts of T cells that contribute to immune responses by secreting effector cytokines and regulating the functions of other innate and adaptive immune cells.
  • Through its patented ex vivo lymphoid niche technology, Smart Immune develops a thymus empowered T cell therapy platform called ProTcell.
  • The Smart Immune ProTcell platform generates allogenic T-cell progenitors that provide fully functional polyclonal T-cells within 3 months through thymic education.

Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

Retrieved on: 
Tuesday, May 17, 2022
FA, Physician, Cancer, B cell, Stem cell, Risk, Company, Population, Aplastic anemia, Blood, RNA transfection, Medicine, Stanford University School of Medicine, MDS, Chronic granulomatous disease, HSCT, HSC, Bone marrow failure, Degenerative disease, AML, Patient, Biology, Sickle cell disease, NASDAQ, Bone marrow, Therapy, Fanconi anemia, COVID-19, GATA2, SCID, Microdeletion syndrome, Research, Definitive, Lists of diseases, Anemia, Probability, Center, Toxicity, Forward-looking statement, Transplant, Safety, Immune reconstitution inflammatory syndrome, Private Securities Litigation Reform Act, SEC, MD, CEO, GLOBE, Pharmaceutical industry, Vaccine, Jasper, Pediatrics

Fanconi Anemia (FA) is a rare but serious blood disorder that prevents the bone marrow from making sufficient new red blood cells.

Key Points: 
  • Fanconi Anemia (FA) is a rare but serious blood disorder that prevents the bone marrow from making sufficient new red blood cells.
  • Treatment may include blood transfusions or medicine to create more red blood cells, but hematopoietic stem cell transplant (HSCT) is the only cure.
  • Primary outcome measures include the number of patients without treatment emergent adverse events following administration of JSP191.
  • While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so.

Rational Vaccines' Herpes Vaccine RVx1001 Shows Promise as a Viral Vector Platform to Express Malaria Proteins and Confer Protection against Malaria Infection in Mice According to a Recent Study Published in Vaccines

Retrieved on: 
Tuesday, May 10, 2022
School, Herpes simplex virus, State Research Center of Virology and Biotechnology VECTOR, Simplex, Mortality, Parasitism, Mouse, Biological life cycle, Company, Travel, Veterinary medicine, Red blood cell, Liver stage antigens, Safety, WHO, Infection, Louisiana State University, Human, Diagnosis, Incidence, Plasmodium falciparum, List of life sciences, Death, Cancer, Disease, UC Davis School of Veterinary Medicine, Guinea, SCID, Liver, LSU, Protein, HSV, Plasmodium yoelii, Risk, Multimedia, Vaccine, Research, Biotechnology, Virology, DRS, Vaccine, Malaria, Plasmodium

WOBURN, Mass. and OXFORD, England, May 10, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced that the Company's attenuated herpes simplex virus type-1 (HSV-1)-vaccine RVx1001 can be utilized as a viral vaccine vector to protect against malaria infections.

Key Points: 
  • Research shows company's novel HSV-1-derived viral vaccine has significant potential to produce vaccines to combat infectious diseases including malaria.
  • The study, "An Attenuated HSV-1 Derived Malaria Vaccine Expressing Liver-Stage Exported Proteins Induces Sterilizing Protection Against Infectious Sporozoite Challenge," was published in Vaccines and can be accessed at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875294/
    The published study reported on the development of a highly efficacious trivalent malaria vaccine using the Rational Vaccines RVx1001 vaccine as a vector.
  • The construction of the HSV-1 vectored vaccine expressed three liver-stage (LS) malaria parasite exported proteins (EXP1, UIS3, and TMP21) as fusion proteins with the VP26 viral capsid protein.
  • "These data show that the Rational Vaccines HSV-1 vaccine can be effectively utilized as a vector platform to protect against malaria and other infectious diseases.

Gene Therapies & Associated Vectors Intellectual Property Landscape 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 15, 2022
Health, Genetics, Patent, DNA, SCID, COVID-19, Adenosine deaminase, Microsoft PowerPoint, RNA, Microsoft Excel, ADA, Lists of diseases, Industry, D, Vaccine, Pharmaceutical industry

The "Gene Therapies & Associated Vectors: Intellectual Property Landscape" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gene Therapies & Associated Vectors: Intellectual Property Landscape" report has been added to ResearchAndMarkets.com's offering.
  • Briefly, a replication defective retrovirus was used to transfect autologous T-cells with a functional copy of the ADA gene, which restored normal immune function.
  • This report summarizes some of the key R&D trends related to gene therapies and affiliated vectors.
  • The report features an extensive study of some of the key historical and contemporary intellectual property (IP) documents (featuring granted patents, patent applications and other documents) describing gene therapies and affiliated vector constructs.

Global Viral Vector Manufacturing Market Trajectory & Analytics Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 6, 2022
Science, Other Science, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Other Health, Virus, Cell, CAGR, Population, Human, Investment, SCID, Growth, Viral vector, AAV, Vaccine, Research, Molecular biology, Prevalence, Genome, Safety, Ageing, COVID-19, Infection, Viral, Modification, Lipoprotein lipase deficiency, Vector (mathematics and physics), Lists of diseases, Toxicity, Pet

The "Viral Vector Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Viral Vector Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Viral vectors are currently being used for vaccines development and gene therapy in addition to their use in molecular biology.
  • Another important property of viral vectors is that they are of low toxicity, having limited impact on cell physiology.
  • In the global Adeno-associated Viral Vectors segment, USA, Canada, Japan, China and Europe will drive the 19.7% CAGR estimated for this segment.

Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting

Retrieved on: 
Thursday, March 31, 2022
Company, Risk, Therapy, Life, Stem cell, Population, NASDAQ, Degenerative disease, Translational medicine, AML, SCID, Forward-looking statement, GATA2, IVIG, Bone marrow, SEC, Probability, CEO, Senior, Private Securities Litigation Reform Act, HSC, MDS, Lists of diseases, CIS, Safety, Biology, Annual general meeting, RNA transfection, Microdeletion syndrome, COVID-19, GLOBE, Immune reconstitution inflammatory syndrome, Transplant, Severe combined immunodeficiency, Sickle cell disease, Physician, Fanconi anemia, Chronic granulomatous disease, Pharmaceutical industry, Vaccine, Jasper, Research, Patient, MD

JSP191 based conditioning may provide these patients with the best chance of a safe and successful transplant and reconstituted immune system.

Key Points: 
  • JSP191 based conditioning may provide these patients with the best chance of a safe and successful transplant and reconstituted immune system.
  • CIS attendees are the primary caregivers for the immune deficient patient population, we are pleased to be able to present this data at the 2022 CIS annual meeting, Ronald Martell, CEO of Jasper.
  • We believe that with our successful clinical efforts, we are one step closer, and uniquely positioned to deliver a targeted non-genotoxic conditioning agent to patients with SCID.
  • Three clinical trials for myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), severe combined immunodeficiency (SCID) and Fanconi anemia are currently enrolling.

Global Viral Vector Manufacturing Market to Reach $1.2 Billion by 2026

Retrieved on: 
Wednesday, March 23, 2022
CAGR, Conditional sentence, Viral vector, Vaccine, Gesellschaft mit beschränkter Haftung, Forecasting, Research, Genetic disorder, Pharma, Adoption, Genome, Mindful Scientific Inc., Vector (mathematics and physics), Thermo Fisher Scientific, Virus, Population, Players, Marketing, SCID, Molecular biology, Ageing, Lipoprotein lipase deficiency, Toxicity, DNA, Merck Group, Investment, Growth, Gendicine, Internet, Intelligence, Lists of diseases, SAN, Cell, Human, Infection, AAV, Diosynth, BioNTech, SV40, Genelux Corporation, Prevalence, Safety, GIA, COVID-19, Viral, Pharmaceutical industry, Pet, Disease, Others, Cancer

SAN FRANCISCO, March 23, 2022 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Viral Vector Manufacturing - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, March 23, 2022 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Viral Vector Manufacturing - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Viral Vector Manufacturing estimated at US$661.8 Million in the year 2022, is projected to reach a revised size of US$1.2 Billion by 2026, growing at a CAGR of 18.5% over the analysis period.
  • The U.S. Market is Estimated at $397 Million in 2022, While China is Forecast to Reach $49 Million by 2026
    The Viral Vector Manufacturing market in the U.S. is estimated at US$397 Million in the year 2022.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 18, 2022
Administration, Company, Risk, Therapy, Stem cell, Acute myeloid leukemia, NASDAQ, MRD, Degenerative disease, AML, MDS, SCID, Growth, Forward-looking statement, Public expenditure, Cash, Bone marrow, Research, SEC, Private Securities Litigation Reform Act, Lists of diseases, Safety, Biology, FA, RNA transfection, Microdeletion syndrome, GLOBE, Transplant, Physician, Toxic epidermal necrolysis, Fanconi anemia, Research and development, Patient, Radiation, Pharmaceutical industry, Vaccine, Jasper

REDWOOD CITY, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for the fiscal year ended December 31, 2021, and provided a business update.

Key Points: 
  • REDWOOD CITY, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for the fiscal year ended December 31, 2021, and provided a business update.
  • Cash and Cash Equivalents: Cash and cash equivalents as of December 31, 2021, were $84.7 million.
  • Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell.
  • Jasper undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.